ID1 regulates U87 human cell proliferation and invasion

Guo,Pin; Lan,Jin; Ge,Jianwei; Mao,Qing; Qiu,Yongming

doi:10.3892/ol.2013.1507

ID1 regulates U87 human cell proliferation and invasion

Authors:
- Pin Guo
- Jin Lan
- Jianwei Ge
- Qing Mao
- Yongming Qiu
View Affiliations

Affiliations: Department of Neurosurgery, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, P.R. China
Published online on: August 1, 2013 https://doi.org/10.3892/ol.2013.1507
Pages: 921-926

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Despite therapeutic advances, the prognosis of patients diagnosed with malignant glioma has not improved in recent years. In particular, the molecular mechanisms that mediate glioma invasion remain poorly understood. The importance of ID1 in promoting tumor invasion and metastasis has recently emerged and a role for ID1 as a possible molecular marker of tumor aggressiveness has been proposed. To investigate the biological function of ID1 in glioblastomas, ID1‑silenced U87 glioblastoma multiforme (GBM) cells were constructed using a small hairpin RNA (shRNA) sequence. The effect of the knockdown of ID1 on proliferation and invasion in these cells was analyzed using the 5‑bromo‑2'‑deoxy‑uridine cell proliferation, Transwell invasion, scratch and cell adhesion assays. Compared with the controls, the U87 cells expressing ID1‑shRNA exhibited a significantly decreased proliferation and invasion capacity (P<0.05), as well as increased cell adhesion. Furthermore, silencing ID1 reduced the expression of c‑Myc, cyclin D1 and β‑catenin, while increasing E‑cadherin expression in U87 cells. This study showed that ID1 regulates the metastatic potential of GBM cells by controlling the epithelial‑mesenchymal transition. Therefore, ID1 is a potential prognostic indicator and therapeutic target in glioblastomas.

View Figures

View References

1	Ferguson SD: Malignant gliomas: diagnosis and treatment. Dis Mon. 57:558–569. 2011. View Article : Google Scholar : PubMed/NCBI
2	Onishi M, Ichikawa T, Kurozumi K and Date I: Angiogenesis and invasion in glioma. Brain Tumor Pathol. 28:13–24. 2011. View Article : Google Scholar : PubMed/NCBI
3	Rampling R, James A and Papanastassiou V: The present and future management of malignant brain tumours: surgery, radiotherapy, chemotherapy. J Neurol Neurosurg Psychiatry. 75(Suppl 2): ii24–ii30. 2004. View Article : Google Scholar : PubMed/NCBI
4	Salhia B, Tran NL, Symons M, Winkles JA, Rutka JT and Berens ME: Molecular pathways triggering glioma cell invasion. Expert Rev Mol Diagn. 6:613–626. 2006. View Article : Google Scholar : PubMed/NCBI
5	Harpold HL, Alvord EC Jr and Swanson KR: The evolution of mathematical modeling of glioma proliferation and invasion. J Neuropathol Exp Neurol. 66:1–9. 2007. View Article : Google Scholar : PubMed/NCBI
6	Okita Y, Narita Y, Miyakita Y, et al: Pathological findings and prognostic factors in recurrent glioblastomas. Brain Tumor Pathol. 29:192–200. 2012. View Article : Google Scholar : PubMed/NCBI
7	Park SG, Jung S, Ryu HH, et al: Role of 14-3-3-beta in the migration and invasion in human malignant glioma cell line U87MG. Neurol Res. 34:893–900. 2012. View Article : Google Scholar : PubMed/NCBI
8	de Groot JF and Gilbert MR: New molecular targets in malignant gliomas. Curr Opin Neurol. 20:712–718. 2007.PubMed/NCBI
9	Bredel M, Bredel C, Juric D, et al: Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas. Cancer Res. 65:8679–8689. 2005. View Article : Google Scholar : PubMed/NCBI
10	Nager M, Bhardwaj D, Cantí C, Medina L, Nogués P and Herreros J: β-Catenin signalling in glioblastoma multiforme and glioma-initiating cells. Chemother Res Pract. 2012:1923622012.
11	Yue X, Lan F, Yang W, et al: Interruption of β-catenin suppresses the EGFR pathway by blocking multiple oncogenic targets in human glioma cells. Brain Res. 1366:27–37. 2010.
12	Sikder HA, Devlin MK, Dunlap S, Ryu B and Alani RM: Id proteins in cell growth and tumorigenesis. Cancer Cell. 3:525–530. 2003. View Article : Google Scholar : PubMed/NCBI
13	Perk J, Iavarone A and Benezra R: Id family of helix-loop-helix proteins in cancer. Nat Rev Cancer. 5:603–614. 2005. View Article : Google Scholar : PubMed/NCBI
14	Coppe JP, Itahana Y, Moore DH, Bennington JL and Desprez PY: Id-1 and Id-2 proteins as molecular markers for human prostate cancer progression. Clin Cancer Res. 10:2044–2051. 2004. View Article : Google Scholar : PubMed/NCBI
15	Gupta GP, Perk J, Acharyya S, et al: ID genes mediate tumor reinitiation during breast cancer lung metastasis. Proc Natl Acad Sci USA. 104:19506–19511. 2007. View Article : Google Scholar : PubMed/NCBI
16	Pillai S, Rizwani W, Li X, et al: ID1 facilitates the growth and metastasis of non-small cell lung cancer in response to nicotinic acetylcholine receptor and epidermal growth factor receptor signaling. Mol Cell Biol. 31:3052–3067. 2011. View Article : Google Scholar : PubMed/NCBI
17	Vandeputte DA, Troost D, Leenstra S, et al: Expression and distribution of id helix-loop-helix proteins in human astrocytic tumors. Glia. 38:329–338. 2002. View Article : Google Scholar : PubMed/NCBI
18	Benezra R, Davis RL, Lockshon D, Turner DL and Weintraub H: The protein Id: a negative regulator of helix-loop-helix DNA binding proteins. Cell. 61:49–59. 1990. View Article : Google Scholar : PubMed/NCBI
19	Kiewitz SD, Kruppa M, Riechers A, König B and Cabrele C: Recognition of the helix-loop-helix domain of the Id proteins by an artificial luminescent metal complex receptor. J Mol Recognit. 21:79–88. 2008. View Article : Google Scholar : PubMed/NCBI
20	Langlands K, Yin X, Anand G and Prochownik EV: Differential interactions of Id proteins with basic-helix-loop-helix transcription factors. J Biol Chem. 272:19785–19793. 1997. View Article : Google Scholar : PubMed/NCBI
21	Xie SQ, Zhang YH, Li Q, et al: 3-Nitro-naphthalimide and nitrogen mustard conjugate NNM-25 induces hepatocellular carcinoma apoptosis via PARP-1/p53 pathway. Apoptosis. 17:725–734. 2012. View Article : Google Scholar : PubMed/NCBI
22	Ciarrocchi A, Piana S, Valcavi R, Gardini G and Casali B: Inhibitor of DNA binding-1 induces mesenchymal features and promotes invasiveness in thyroid tumour cells. Eur J Cancer. 47:934–945. 2011. View Article : Google Scholar : PubMed/NCBI
23	Lin CQ, Singh J, Murata K, et al: A role for Id-1 in the aggressive phenotype and steroid hormone response of human breast cancer cells. Cancer Res. 60:1332–1340. 2000.PubMed/NCBI
24	Guo Q, Guo P, Mao Q, et al: ID1 affects the efficacy of radiotherapy in glioblastoma through inhibition of DNA repair pathways. Med Oncol. 30:3252013. View Article : Google Scholar : PubMed/NCBI
25	Ling MT, Wang XH, Zhang XM and Wong YC: The multiple roles of Id-1 in cancer progression. Differentiation. 74:481–487. 2006. View Article : Google Scholar : PubMed/NCBI
26	Ahmad A, Aboukameel A, Kong D, et al: Phosphoglucose isomerase/autocrine motility factor mediates epithelial-mesenchymal transition regulated by miR-200 in breast cancer cells. Cancer Res. 71:3400–3409. 2011. View Article : Google Scholar
27	Wells A, Yates C and Shepard CR: E-cadherin as an indicator of mesenchymal to epithelial reverting transitions during the metastatic seeding of disseminated carcinomas. Clin Exp Metastasis. 25:621–628. 2008. View Article : Google Scholar : PubMed/NCBI
28	Borkar SA, Lakshmiprasad G, Subbarao KC, et al: Giant cell glioblastoma in the pediatric age group: Report of two cases. J Pediatr Neurosci. 8:38–42. 2013. View Article : Google Scholar : PubMed/NCBI
29	Qi S, Song Y, Peng Y, et al: ZEB2 mediates multiple pathways regulating cell proliferation, migration, invasion, and apoptosis in glioma. PLoS One. 7:e388422012. View Article : Google Scholar : PubMed/NCBI
30	Cheng YJ, Tsai JW, Hsieh KC, et al: Id1 promotes lung cancer cell proliferation and tumor growth through Akt-related pathway. Cancer Lett. 307:191–199. 2011. View Article : Google Scholar : PubMed/NCBI
31	Tobin NP, Sims AH, Lundgren KL, Lehn S and Landberg G: Cyclin D1, Id1 and EMT in breast cancer. BMC Cancer. 11:4172011. View Article : Google Scholar : PubMed/NCBI
32	Meng Q, Jia Z, Wang W, Li B, Ma K and Zhou C: Inhibitor of DNA binding 1 (Id1) induces differentiation and proliferation of mouse embryonic carcinoma P19CL6 cells. Biochem Biophys Res Commun. 412:253–259. 2011. View Article : Google Scholar : PubMed/NCBI
33	Geng H, Rademacher BL, Pittsenbarger J, et al: ID1 enhances docetaxel cytotoxicity in prostate cancer cells through inhibition of p21. Cancer Res. 70:3239–3248. 2010. View Article : Google Scholar : PubMed/NCBI
34	Anido J, Sáez-Borderías A, Gonzàlez-Juncà A, et al: TGF-β Receptor Inhibitors Target the CD44(high)/Id1(high) Glioma-Initiating Cell Population in Human Glioblastoma. Cancer Cell. 18:655–668. 2010.
35	Barrett LE, Granot Z, Coker C, et al: Self-renewal does not predict tumor growth potential in mouse models of high-grade glioma. Cancer Cell. 21:11–24. 2012. View Article : Google Scholar : PubMed/NCBI
36	Sarmiere PD and Bamburg JR: Regulation of the neuronal actin cytoskeleton by ADF/cofilin. J Neurobiol. 58:103–117. 2004. View Article : Google Scholar : PubMed/NCBI
37	Nager M, Bhardwaj D, Canti C, et al: β-catenin signaling in glioblastoma multiforme and glioma-initiating cells. Chemother Res Pract. 2012:1923622012.